Cargando…

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond

Alemtuzumab is a humanized monoclonal antibody against CD52 (cluster of differentiation 52) and is approved for the therapy of relapsing-remitting multiple sclerosis. The application of alemtuzumab leads to a rapid, but long-lasting depletion predominantly of CD52-bearing B and T cells with reprogra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruck, Tobias, Bittner, Stefan, Wiendl, Heinz, Meuth, Sven G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519957/ https://www.ncbi.nlm.nih.gov/pubmed/26204829 http://dx.doi.org/10.3390/ijms160716414

Ejemplares similares

Long-term efficacy of alemtuzumab in polymyositis
por: Ruck, Tobias, et al.
Publicado: (2015)

ALAIN01—Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential
por: Ruck, Tobias, et al.
Publicado: (2016)

Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis—A Longitudinal Observational Study
por: Riepl, Ester, et al.
Publicado: (2018)

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis
por: Keller, Christian W., et al.
Publicado: (2019)

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders
por: Brummer, Tobias, et al.
Publicado: (2021)

Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
por: Möhn, Nora, et al.
Publicado: (2019)

Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment
por: Haas, Jürgen, et al.
Publicado: (2019)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Rolfes, Leoni, et al.
Publicado: (2020)

Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Huntemann, Niklas, et al.
Publicado: (2021)

DTI detects water diffusion abnormalities in the thalamus that correlate with an extremity pain episode in a patient with multiple sclerosis()
por: Deppe, Michael, et al.
Publicado: (2013)

Case Report: Adult Still’s Disease in an Alemtuzumab-Treated Multiple Sclerosis Patient
por: Krämer, Julia, et al.
Publicado: (2020)

Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs—A Systematic Review
por: Rolfes, Leoni, et al.
Publicado: (2019)

Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study
por: Ruck, Tobias, et al.
Publicado: (2019)

Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells
por: Ruck, Tobias, et al.
Publicado: (2018)

Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis
por: Wiendl, Heinz, et al.
Publicado: (2015)

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2022)

Alemtuzumab for the treatment of multiple sclerosis
por: Willis, Mark D, et al.
Publicado: (2015)

Alemtuzumab in the treatment of multiple sclerosis
por: Fernandez, Óscar
Publicado: (2014)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Teriflunomide and Its Mechanism of Action in Multiple Sclerosis
por: Bar-Or, Amit, et al.
Publicado: (2014)

Increased cortical curvature reflects white matter atrophy in individual patients with early multiple sclerosis
por: Deppe, Michael, et al.
Publicado: (2014)

Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis
por: Eschborn, Melanie, et al.
Publicado: (2021)

Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity
por: Ruck, Tobias, et al.
Publicado: (2022)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Murine K(2P)5.1 Deficiency Has No Impact on Autoimmune Neuroinflammation due to Compensatory K(2P)3.1- and K(V)1.3-Dependent Mechanisms
por: Bittner, Stefan, et al.
Publicado: (2015)

Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2019)

Blood-brain barrier modeling: challenges and perspectives
por: Ruck, Tobias, et al.
Publicado: (2015)

Thinking outside the box: non-canonical targets in multiple sclerosis
por: Bierhansl, Laura, et al.
Publicado: (2022)

Early and Degressive Putamen Atrophy in Multiple Sclerosis
por: Krämer, Julia, et al.
Publicado: (2015)

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
por: Rolfes, Leoni, et al.
Publicado: (2021)

Combined Neurofilament Light and Optical Coherence Tomography Better Predicts Multiple Sclerosis Disease Activity Than Either Measure Alone
por: Krämer, Julia, et al.
Publicado: (2021)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

A β-Lactam Antibiotic Dampens Excitotoxic Inflammatory CNS Damage in a Mouse Model of Multiple Sclerosis
por: Melzer, Nico, et al.
Publicado: (2008)

Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
por: Babij, Rachel, et al.
Publicado: (2015)

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
por: Dubey, Divyanshu, et al.
Publicado: (2015)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5m89itbktdrct8utgcaummggc0